Biogen Inc

NASDAQ: BIIB
$157.90
-$0.11 (-0.1%)
Closing Price on November 22, 2024

BIIB Articles

The top analyst upgrades, downgrades and other research calls from Thursday include AMD, Biogen, Capital One, Intuit, Jinko Solar, Micron Technology, Albermarle and Alnylam Pharmaceuticals.
The top analyst upgrades, downgrades and other research calls from Wednesday include Biogen, Electronic Arts, Gap, Intuit, Johnson & Johnson, 3M, Intercept Pharmaceutical and AutoZone.
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
The August 15 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The top analyst upgrades, downgrades and other research calls from Wednesday include Apple, Caterpillar, Pfizer, Royal Caribbean, Shopify, Under Armour and Walmart.
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for aggressive...
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The June 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has...
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Friday include AK Steel, Altice USA, Biogen, Caterpillar, Gilead Sciences and Oracle.
Most of the large biotech outfits in America have gone into a limbo mode. Alexion Pharmaceuticals fits that bill despite its more than $26 billion market cap. Is it possible that some real good...
The top analyst upgrades, downgrades and other research calls from Monday include Amazon.com, Biogen, Costco Wholesale, Kroger, Travelers and Wayfair.